A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors
This study is testing an experimental cancer medication called IDE892, either alone or combined with another drug, to see how well it works and how safe it is for patients. It is specifically designed for people with advanced solid tumors that have a specific genetic change known as an MTAP deletion.
You may be eligible if you are 18 or older and have been diagnosed with an advanced cancer that has a confirmed MTAP deletion. Participants must be willing to provide blood and tumor tissue samples to help researchers understand the genetic makeup of their disease.
During the study, you will receive the experimental medication and have regular check-ups to monitor your health. You will also provide blood samples throughout the trial so the doctors can see how your body reacts to the treatment.
This study is currently recruiting volunteers at several locations in the United States, including sites in California, Washington D.C., and Florida.
- 1This study investigates a new treatment approach for specific advanced cancers with an MTAP genetic deletion.
- 2Participation involves receiving an experimental medication and providing regular blood and tissue samples.
- 3The goal is to determine if this new treatment is safe and effective for patients who have limited options.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.